55 PARK LANE, LONDON, X0
Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
Announces Chief Development Officer and Director Acquires Shares
Announces Director Acquires Shares
Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
Partial Exercise of Option to Purchase Additional Shares
Abstract Selected for Presentation at Premier Global Ophthalmology Congress
Announces Pricing of $20 Million Public Offering of Ordinary Shares
.3
Amended Annual and Transition Report of Foreign Private Issuers
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
NT 20-F
Free Writing Prospectus
Submission Upload